Sidney Kimmel Cancer Center — Jefferson Health names deputy director
Click Here to Manage Email Alerts
Andrew E. Aplin, PhD, has been appointed deputy director for scientific strategy at Sidney Kimmel Cancer Center — Jefferson Health.
Aplin will help guide strategic research priorities to ensure the cancer center successfully delivers advanced, personalized care. In addition, he will foster collaborations among basic, translational, clinical and population science researchers, as well as lead the cancer center’s next NCI designation renewal.
Aplin also serves as associate director for basic research and professor in cancer research.
“I look forward to enhancing collaborative and programmatic approaches within the [Sidney Kimmel Cancer Center] and beyond [because] they are important for the depth and breadth of research within the cancer center,” Aplin said in a press release.
Aplin joined Jefferson in 2008 as associate professor in cancer biology. He became associate director for basic research in 2015.
Aplin’s research focuses on how melanoma develops resistance to targeted therapies. Members of his lab are studying ways to alter the tumor microenvironment so tumors better respond to immune checkpoint inhibitors.
“Dr. Aplin is an internationally respected scientist whose laboratory findings have translated to groundbreaking clinical trials that are now available to [patients with] skin and uveal melanoma,” Andrew Chapman, DO, interim enterprise director of Sidney Kimmel Cancer Center and executive vice president of oncology services at Jefferson Health, said in the release. “It is clear that [Sidney Kimmel Cancer Center] will have an even greater impact in translating our research discoveries to the clinic under Dr. Aplin’s leadership, and we are confident that he will successfully support our continued growth and commitment to research and discovery.”
Read more about
Click Here to Manage Email Alerts